Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy

Completed

Conditions: Coronary Artery Disease
Ischemia

First Posted Date: 2010-08-03

Last Posted Date: 2017-05-24

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 31

Registration Number: NCT01174095

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States

Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)

Terminated

Conditions: Type 2 Diabetes Mellitus
Diabetes Mellitus

First Posted Date: 2010-07-30

Last Posted Date: 2020-07-31

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 450

Registration Number: NCT01172743

Locations: 🇶🇦
Hamad Medical Corporation, Doha, Qatar

Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)

Phase 1

Completed

Conditions: Batten Disease
Late-Infantile Neuronal Ceroid Lipofuscinosis

Interventions: Biological: AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies
Biological: AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies

First Posted Date: 2010-07-13

Last Posted Date: 2021-02-02

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 12

Registration Number: NCT01161576

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: clarithromycin
Drug: Pomalidomide

First Posted Date: 2010-07-09

Last Posted Date: 2019-06-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 121

Registration Number: NCT01159574

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Phase 1

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: 90Y-epratuzumab tetraxetan
Biological: veltuzumab

First Posted Date: 2010-06-22

Last Posted Date: 2018-02-22

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 4

Registration Number: NCT01147393

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: bortezomib (Velcade)
Drug: cyclophosphamide
Drug: Plerixafor
Drug: G-CSF

First Posted Date: 2010-06-22

Last Posted Date: 2019-12-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 47

Registration Number: NCT01146834

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
New York University Cancer Institute, New York, New York, United States
🇺🇸
Columbia Presbyterian Medical Center):, New York, New York, United States

and more 2 locations

Assessing the Impact of Health Information Exchange (HIE) on Healthcare Utilization

Completed

Conditions: Health Care Utilization
Health Information Technology
Health Information Exchange
Virtual Health Record

Interventions: Other: Virtual Health Record (VHR)

First Posted Date: 2010-06-22

Last Posted Date: 2018-08-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 218766

Registration Number: NCT01147328

Locations: 🇺🇸
HealtheLink, Buffalo, New York, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
Rochester RHIO, Rochester, New York, United States

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: thalidomide
Drug: lenalidomide
Biological: rituximab

First Posted Date: 2010-05-18

Last Posted Date: 2022-01-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 15

Registration Number: NCT01125176

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Treatment of Polycythemia Vera With Gleevec

Phase 2

Completed

Conditions: Polycythemia Vera

Interventions: Drug: Gleevec

First Posted Date: 2010-05-11

Last Posted Date: 2010-05-17

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 36

Registration Number: NCT01120821

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: azacytidine
Drug: vorinostat

First Posted Date: 2010-05-11

Last Posted Date: 2017-04-10

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 17

Registration Number: NCT01120834

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy